

Roberto Padoan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3523654/roberto-padoan-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

246
citations

7
h-index

15
g-index

51
ext. papers

388
ext. citations

4.6
avg, IF

2.41
L-index

#	Paper	IF	Citations
29	SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. <i>Journal of Autoimmunity</i> , 2020 , 112, 102502	15.5	59
28	Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment. <i>Journal of Immunology Research</i> , 2018 , 2018, 5072582	4.5	22
27	Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes. <i>Clinical Rheumatology</i> , 2018 , 37, 1075-1083	3.9	21
26	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016 , 95, e5506	1.8	11
25	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. <i>Journal of Autoimmunity</i> , 2020 , 108, 102397	15.5	10
24	Cogan's syndrome: new therapeutic approaches in the biological era. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 781-788	5.4	7
23	Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 3225-3227.e2	5.4	7
22	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , 2021 , 57,	13.6	7
21	No Differences in Nasal Tissue Inflammatory Cells and Adhesion Molecules (iCAM-1 and vCAM-1) Based on the Comparison of EGPA With Eosinophilic Chronic Sinusitis With Polyposis. <i>American Journal of Rhinology and Allergy</i> , 2019 , 33, 395-402	2.4	5
20	Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1441-1448	5.3	5
19	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , 2021 , 74, 295	9.5	5
18	Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis With Polyangiitis. <i>Journal of Clinical Rheumatology</i> , 2018 , 24, 197-202	1.1	3
17	Fully integrated 18F-FDG PET/MR in large vessel vasculitis. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 ,	1.4	2
16	Nasal polyps in eosinophilic granulomatosis with polyangiitis: Structured histopathology and CD105 expression. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2020 , 41, 102661	2.8	2
15	107. FULLY INTEGRATED 18F-FDG PET/MR IN LARGE VESSEL VASCULITIS. <i>Rheumatology</i> , 2019 , 58,	3.9	1
14	Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA. <i>Clinical Rheumatology</i> , 2021 , 40, 1949-1957	3.9	1
13	FRI0387 Peripheral Neuropathy in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Incat Disability Score To Evaluate Damage and To Predict Long Term Outcome in 50 Patients. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 574.3-575	2.4	0

12	Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis.. <i>Autoimmunity Reviews</i> , 2021 , 21, 103018	13.6	o
11	IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2021 , 124, 102725	15.5	o
10	Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 107-113	2.2	o
9	Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 107-113	2.2	o
8	AB0551 Clinical Application of Two Different Disease Activity Scores for ENT Involvement in Granulomatosis with Polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1093.1-1093	2.4	
7	FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 689.1-690	2.4	
6	FRI0214 PERSISTENT LOW-GRADE FDG-PET VASCULAR INFLAMMATION IN REMITTED LVV-GCA PATIENTS IS ASSOCIATED TO A SIGNIFICANT HIGH RISK OF RELAPSE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 690.2-691	2.4	
5	SAT0243 SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1064-1065	2.4	
4	SAT0245 RENAL INVOLVEMENT AT ONSET IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS: A MAJOR INDEPENDENT RISK FACTOR FOR RENAL RELAPSE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1065.2-1065	2.4	
3	FRI0178 Anti-Etanercept Antibodies and Etanercept Leves Levels in Rheumatoid Arthritis Patients Treated with Low and Full-Dose Etanercept in Das28 Remission. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 494.1-494	2.4	
2	Diagnostic and prognostic role of renal histopathology in rheumatic diseases. <i>Reumatismo</i> , 2018 , 70, 165-177	1.1	
1	Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 124, 188-194	2.2	